A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme

Many B cell cancers are characterized in part by the dysregulation of the NF-κB signaling pathway. A new study identifies somatic mutations in TNFAIP3, the gene encoding the NF-κB inhibitor A20, in Hodgkin lymphomas and primary mediastinal lymphomas. These data reveal the role of A20 as a tumor supp...

Descripción completa

Detalles Bibliográficos
Autores principales: Malynn, Barbara A., Ma, Averil
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2009
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715039/
https://www.ncbi.nlm.nih.gov/pubmed/19380636
http://dx.doi.org/10.1084/jem.20090765
_version_ 1782169726755012608
author Malynn, Barbara A.
Ma, Averil
author_facet Malynn, Barbara A.
Ma, Averil
author_sort Malynn, Barbara A.
collection PubMed
description Many B cell cancers are characterized in part by the dysregulation of the NF-κB signaling pathway. A new study identifies somatic mutations in TNFAIP3, the gene encoding the NF-κB inhibitor A20, in Hodgkin lymphomas and primary mediastinal lymphomas. These data reveal the role of A20 as a tumor suppressor protein.
format Text
id pubmed-2715039
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-27150392009-11-11 A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme Malynn, Barbara A. Ma, Averil J Exp Med Commentary Many B cell cancers are characterized in part by the dysregulation of the NF-κB signaling pathway. A new study identifies somatic mutations in TNFAIP3, the gene encoding the NF-κB inhibitor A20, in Hodgkin lymphomas and primary mediastinal lymphomas. These data reveal the role of A20 as a tumor suppressor protein. The Rockefeller University Press 2009-05-11 /pmc/articles/PMC2715039/ /pubmed/19380636 http://dx.doi.org/10.1084/jem.20090765 Text en © 2009 Malynn and Ma This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
spellingShingle Commentary
Malynn, Barbara A.
Ma, Averil
A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme
title A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme
title_full A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme
title_fullStr A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme
title_full_unstemmed A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme
title_short A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme
title_sort a20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715039/
https://www.ncbi.nlm.nih.gov/pubmed/19380636
http://dx.doi.org/10.1084/jem.20090765
work_keys_str_mv AT malynnbarbaraa a20takesontumorstumorsuppressionbyanubiquitineditingenzyme
AT maaveril a20takesontumorstumorsuppressionbyanubiquitineditingenzyme

Ejemplares similares